RALEIGH, N.C.--(BUSINESS WIRE)--April 19, 2006--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP - News) today announced the successful completion and outcome of a multi-center superiority trial to compare the colon cleansing, patient tolerability, patient preference and safety profile of the Company’s recently-approved OsmoPrep(TM) Tablets and HalfLytely® with Bisacodyl Tablets Bowel Prep Kit.
